<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01341249</url>
  </required_header>
  <id_info>
    <org_study_id>SNUCPT11_DW224aa</org_study_id>
    <nct_id>NCT01341249</nct_id>
  </id_info>
  <brief_title>A Study to Compare the Pharmacokinetic Profiles of DW224aa and DW224a</brief_title>
  <official_title>Clinical Trial to Compare the Pharmacokinetic Profiles of DW224aa (Aspartate) Tablet and DW224a (Hydrochloride) Capsule After a Single Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dong Wha Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare and explore pharmacokinetics of zabofloxacin, the
      main component of DW224aa(Test drug) and DW224a(Reference drug).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of zabofloxacin in plasma</measure>
    <time_frame>Up to 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of zabofloxacin in plasma</measure>
    <time_frame>Up to 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax of zabofloxacin in plasma</measure>
    <time_frame>Up to 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>terminal half-life (t1/2) of zabofloxacin in plasma</measure>
    <time_frame>Up to 48h</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F of zabofloxacin in plasma</measure>
    <time_frame>Up to 48h</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>DW224aa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DW224aa given by oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DW224a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DW224aa given by oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental DW224aa</intervention_name>
    <description>DW224aa tablet, single dose</description>
    <arm_group_label>DW224aa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental DW224a</intervention_name>
    <description>DW224a capsule, single dose</description>
    <arm_group_label>DW224a</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a healthy adult male within the range of 20 to 45 years old at the time of screening

          -  one with weight of more than 55kg, in the range of IBW 20%

               -  IBW(kg)={height(cm)-100}*0.9

          -  one who understood completely about this study after the detailed explanation is
             given, decided to volunteer and gave written informed consent to participate in study
             in compliance with the requirement of the entire protocol.

        Exclusion Criteria:

          -  one with clinically significant disease in liver, kidney, nerve system, respiratory
             system, endocrine system, blood, tumor, urinary system, cardiovascular system, mental
             disease or with medical history

          -  one with gastrointestinal disease or with gastrointestinal surgical history which can
             affect the absorption of the investigational drug.

          -  one who is allergic or has clinically significant allergic history to the quinolone
             antibiotics, or to other drugs(Aspirin, antibiotics, etc)

          -  one who shows the following result in clinical laboratory test: AST,ALT&gt;1.25 times of
             the upper limit of normal range

          -  one who has confirmed positive at serological tests (HBs antigen, HCV antibody and HIV
             antibody)

          -  one who has drug abuse history or positive result at urine screening tests
             (cannabinoid, opioid, amphetamine, cocaine, barbiturate, benzodiazepine)

          -  one who has taken any prescribed drugs, herbal agents or crude drugs within 2 weeks
             before study drug administration, or who has taken any over-the-counter (OTC) drugs or
             vitamins (Investigators will determine his eligibility by considering the effect of
             the drug on his safety or pharmacokinetic results in case other inclusion/exclusion
             criteria is satisfied.)

          -  one who has participated in other clinical study within 2 months before study drug
             administration

          -  one who donated whole blood within 2 months or component blood within 1 month or who
             are donated within 1 month before the treatment

          -  one who drank Over 21 units/week of alcohol or subjects who would not be able to stop
             drinking alcohol during the hospitalization

          -  one who are Heavy smoker more than 10 cigarettes/day within 3 months prior to
             screening or subjects who would not be able to stop smoking during the hospitalization

          -  one who had a beverage containing caffeine, drank alcohol, or smoked within 48hrs
             before the hospitalization or who had a beverage containing grapefruits during the
             hospitalization

          -  one with clinically significant observations considered as unsuitable based on medical
             judgment by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung Sang Yu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trials Center, Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2011</study_first_posted>
  <last_update_submitted>July 15, 2011</last_update_submitted>
  <last_update_submitted_qc>July 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chang-Soo Cho</name_title>
    <organization>DONG WHA PHARMACEUTICAL CO., LTD</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

